Marqeta Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Marqeta Inc trades at $17.22 (market cap $1.85B), while State Street SPDR S&P Biotech ETF trades at $154.42. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | XBI | |
|---|---|---|
Market Cap | $1.85B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $27.32 | $164.28 |
52-Week Low | $15.04 | $85.16 |
Enterprise Value | $1.15B | — |
Trailing returns across standard periods
Latest headlines on both assets
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →